Tirzepatide: A Systematic Update

Тирзепатид: систематический обзор новых данных
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, Stanislovas S. Jankauskas, Pasquale Mone, Gaetano Santulli
2022-11-23

SURPASS clinical trialsTirzepatidedual GIP/GLP-1 receptor agonistglycemic controltype 2 diabetes
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. GIP and GLP1 are incretin hormones: they are released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity secreting insulin. GIP and GLP1 also have other metabolic functions. GLP1, in particular, reduces food intake and delays gastric emptying. Moreover, Tirzepatide has been shown to improve blood pressure and to reduce Low-Density Lipoprotein (LDL) cholesterol and triglycerides. Tirzepatide efficacy and safety were assessed in a phase III SURPASS 1-5 clinical trial program. Recently, the Food and Drug Administration approved Tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise, to achieve better glycemic blood levels in patients with diabetes. Other clinical trials are currently underway to evaluate its use in other diseases. The scientific interest toward this novel, first-in-class medication is rapidly increasing. In this comprehensive and systematic review, we summarize the main results of the clinical trials investigating Tirzepatide and the currently available meta-analyses, emphasizing novel insights into its adoption in clinical practice for diabetes and its future potential applications in cardiovascular medicine.
1
Beyond glycemic control, tirzepatide has been associated with reduced food intake, delayed gastric emptying, improved blood pressure, and lower LDL cholesterol and triglycerides.
2
Its efficacy and safety were evaluated in the phase III SURPASS 1–5 clinical trial program.
3
Ongoing clinical trials are evaluating tirzepatide for additional diseases, including potential future applications in cardiovascular medicine.
4
The FDA approved subcutaneous tirzepatide as monotherapy or combination therapy with diet and exercise for improving glycemic control in patients with diabetes.
5
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist designed to improve glucose control through complementary incretin effects.

Tirzepatide therapy in patients with diabetes

Efficacy, safety, glycemic control, metabolic effects, and potential clinical applications of tirzepatide

Publication Details
Publication Date
2022-11-23
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Imma Forzano
Fahimeh Varzideh
Roberta Avvisato
Stanislovas S. Jankauskas
Pasquale Mone
Gaetano Santulli
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%